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Abstract
 
Chronic airway rejection is characterized by prolonged inflammation, epithelial damage, and
eventual luminal obliterative bronchiolitis (OB). In cardiac allografts, the inducible nitric oxide
synthase (iNOS) promotes acute rejection but paradoxically reduces neointimal formation, the
hallmark of chronic rejection. The specific roles of NOS isoforms in modulating lymphocyte
traffic and airway rejection are not known. Using a double lumen mouse tracheal transplant
model, tracheal grafts from B10.A (allo) or C57BL/6J (iso) mice were transplanted into cy-
closporine-treated wild-type (WT) iNOS
 
 
 
/
 
  
 
or endothelial NOS (eNOS)
 
 
 
/
 
  
 
recipients. OB
was observed in WT tracheal allografts at 3 weeks (53 
 
  
 
2% luminal occlusion vs. 17 
 
  
 
1% for
isografts, P 
 
  
 
0.05) with sites of obstructive lesion formation coinciding with areas of CD3
 
 
 
CD8
 
  
 
T cell–rich lymphocytic bronchitis. In contrast, allografts in iNOS
 
 
 
/
 
  
 
recipients exhib-
ited reductions in local expression of proinflammatory chemokines and cytokines, graft T cell
recruitment and apoptosis, and luminal obliteration (29 
 
  
 
2%, P 
 
  
 
0.05 vs. WT allografts).
Recipient eNOS deficiency, however, suppressed neither chemokine expression, lymphocyte
infiltration, nor airway occlusion (54 
 
  
 
2%). These data demonstrate that iNOS exacerbates lu-
minal obliteration of airway allografts in contrast with the known suppression by iNOS of car-
diac allograft vasculopathy. Because iNOS
 
 
 
/
 
  
 
airways transplanted into WT allograft hosts are
not protected from rejection, these data suggest that iNOS expressed by graft-infiltrating leu-
kocytes exerts the dominant influence on airway rejection.
Key words: lung transplantation • allograft • obliterative bronchitis • apoptosis • nitric oxide 
synthase
 
Introduction
 
Obliterative bronchiolitis (OB)
 
*
 
 is an irreversible patho-
logic hallmark of chronic airway rejection, which has an
immunologic basis and eventuates in fibrous obliteration of
the terminal airways (1). Development of OB represents
the primary cause of late morbidity and death after lung
transplantation (2). Histologically, OB develops after an
initial period marked by an influx of inflammatory cells
within airway epithelium (3), recognized as a lymphocytic
bronchitis/bronchiolitis (LB; 4). LB is thought to be a re-
versible airway inflammatory process linking acute rejec-
tion episodes to subsequent airway damage and fibrosis
characteristic of OB, and is believed to be a harbinger of
OB (5). Therefore, the appearance of LB serves as a win-
dow into ongoing and potentially reversible airway de-
struction. Despite histological recognition of LB and OB
on the pathological spectrum of chronic airway rejection,
little is known about potential molecular mechanisms link-
ing the two processes.
One potential link, which served as the focus for this in-
vestigation, is endogenous formation of nitric oxide (NO)
gas and the enzymes responsible for its synthesis. Because
NO synthases (NOS) are expressed in abundance in the
lungs (6–8), have known immunomodulatory functions,
and pathological specimens taken from patients with OB
exhibit increased expression of inducible NOS (iNOS; 9,
10), we hypothesized that NOS expression may play a crit-
ical role in the development of both LB and OB. Addi-
tional histological evidence for a pathological role for ex-
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Abbreviations used in this paper:
 
 BrdU, bromodeoxyuridine; EL, epithe-
lial layer; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric
oxide synthase; LB, lymphocytic bronchitis/bronchiolitis; L-NIL, 
 
N
 
6
 
-(1-
 
iminoethyl)-
 
l
 
-lysine dihydrochloride; MIP-1
 
 
 
, macrophage inflammatory
protein 1
 
 
 
; NO, nitric oxide; NOS, NO synthase(s); OB, obliterative bron-
chiolitis; RANTES, regulated on activation normal T cell expressed
and secreted; RPA, ribonuclease protection assay; SEL, subepithelial
layer; TUNEL, terminal deoxynucleotidyltransferase–mediated dUTP-
digoxigenin nick-end labeling; vWf, von Willebrand factor. 
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cessive NO in airway tissue damage and OB comes from
the examination of pathological OB specimens, in which
immunoreactivity for nitrotyrosine (11) is detected. This
provides evidence of the fleeting presence of peroxynitrite
(12), a cytotoxic reaction product of NO and superoxide
that is capable of triggering apoptosis (13–15). Several cir-
cumstantial lines of evidence also point to a pathological
role for excessive NO production in development of OB.
NO promotes the recruitment of CD8
 
  
 
T cells to inflam-
matory sites (16). In the airways, NO derived from iNOS
appears to increase chemokine expression and thereby in-
duce airway inflammation (17, 18). The CC chemokines
(macrophage inflammatory protein-1
 
  
 
[MIP-1
 
 
 
] and reg-
ulated on activation normal T cell expressed and secreted
[RANTES]) induce the directional migration of mono-
cytes and T cells, which have been implicated as early me-
diators of lung allograft rejection (19). IL-1
 
 
 
, a major
proinflammatory mediator and amplifier of the pulmonary
immune response (20), induces apoptosis of lung fibro-
blasts via NO production (21). The tumor suppressor p53
accumulates in response to NO-induced apoptosis (22)
and promotes apoptosis during cardiac allograft rejection
(23). Theoretically, these chemotactic and proapoptotic
actions of NO could account for several pathophysiologic as-
pects of the pulmonary allogeneic inflammatory response by
regulating the recruitment of monocytes into the target sites
(24, 25), inducing apoptosis of graft stromal or parenchymal
cells, or activating apoptotic signaling pathways to delete acti-
vated lymphocytes to promote graft acceptance (26, 27).
In the general transplant literature, there are dichoto-
mous reports as to the potential role of NO and NOS in
rejection. iNOS appears to have a detrimental role in car-
diac allograft rejection, as its expression is strongly associ-
ated with histologic evidence of rejection (28) and its
blockade (with aminoguanidine) reduces the intensity of
the cellular infiltrates and myocytolysis, pathological hall-
marks of cardiac allograft rejection (29). However, rather
than reducing chronic cardiac allograft rejection, absence of
the iNOS gene exacerbated cardiac transplant arteriosclero-
sis in a murine model of cardiac transplantation (30). In a
rat model of heterotopic tracheal transplantation, adminis-
tration of aminoguanidine (to block NOS, particularly
iNOS) resulted in accelerated lesion development although
surprisingly, there was no affect on the number of graft-
infiltrating CD4
 
  
 
or CD8
 
  
 
T cells (31). To reconcile these
apparent discrepancies and to determine whether the en-
dothelial NOS (eNOS) or inducible isoforms of NOS par-
ticipate in LB or OB development, these studies used a
new murine tracheal transplant model that permits airflow
through the transplanted conduit airway.
From an immunological vantage point, apoptosis of ef-
fector T cell populations may serve an important immuno-
modulatory role. Apoptotic cells have been identified in re-
jecting allografts, including the heart (23, 32, 33), kidneys
(34), and liver (35), and this process appears to be pro-
moted by iNOS induction (23, 32). However, apoptosis of
infiltrating inflammatory cells may not necessarily be a bad
thing. Clearance of infiltrating T lymphocytes through ap-
 
optosis associated with iNOS expression may support a
mechanism of allograft acceptance (36). These experiments
were designed to determine the role of recipient iNOS or
eNOS in the recruitment and apoptosis of infiltrating in-
flammatory cells and their impact on the subsequent devel-
opment of LB and the establishment of OB.
 
Materials and Methods
 
Mice.
 
Inbred male B10.A (H2
 
a
 
), C57BL/6J (H2
 
b
 
), iNOS-
deficient (C57BL/6-Nos2
 
tm1Lau
 
), or eNOS-deficient (C57BL/6J-
Nos3
 
tm1Unc
 
) mice backcrossed over 10 generations on the C57BL/6J
background were purchased from The Jackson Laboratory. All
mice were from 7–10 wk old (25–30 g). Isogeneic tracheal trans-
plants were performed using C57BL/6J mice as both recipients
and donors. Allogeneic (B10.A) tracheal grafts were harvested and
transplanted into WT (C57BL/6J), iNOS
 
 
 
/
 
 
 
, or eNOS
 
 
 
/
 
  
 
recip-
ient mice. To ascertain the involvement of iNOS induction in the
rejection process, WT or eNOS
 
 
 
/
 
  
 
recipient mice were given the
selective iNOS inhibitor, 
 
N
 
6
 
-(1-iminoethyl)-
 
l
 
-lysine dihydro-
chloride (L-NIL; Cayman Chemical), at a daily dose of 5 mg/kg
intraperitoneally (37) for 3 wk after transplantation. Moreover, to
specifically determine the role of epithelial versus leukocyte-
derived iNOS, we also performed transplantation experiments using
iNOS
 
 
 
/
 
  
 
donor (C57BL/6-Nos2
 
tm1Lau
 
) airway allografts trans-
planted into iNOS
 
 
 
/
 
  
 
recipient (B10.A) mice. All experiments
were performed according to a protocol approved by the Institu-
tional Animal Care and Use Committee at Columbia University
in accordance with American Association for Accreditation of
Laboratory Animal Care guidelines.
 
Tracheal Transplantation and Immunosuppression.
 
After anesthe-
tizing mice with 2 mg intraperitoneal ketamine (Fort Dodge
Labs) and 0.2 mg xylazine (American Animal Labs), donor mice
were exsanguinated and whole trachea was exposed with blunt
dissection from surrounding tissue through a midline incision un-
der sterile conditions. The trachea was then transected below the
cricoid cartilage, distal to the carinal bifurcation. The tracheal
graft was placed on a sterilized gauze moistened with saline until
the time of transplantation (within 10 min of harvest).
Recipient mice were similarly anesthetized. After shaving a
small area on the anterior neck and preparing with iodine alcohol
solution, the whole trachea was exposed and two round buttons
of tissue were removed (matched in size and aligned with the
open ends of the donor tracheal segment; see Fig. 1 A). The distal
recipient orifice was positioned in the sixth intercartilaginous
space and the proximal orifice was placed immediately subjacent
to the cricoid cartilage area. Distal and proximal tracheal anasto-
moses were performed end to side using continuous 10-0
polypropylene sutures. Surgical wounds were repaired with a
two-layer closer technique (anterior cervical muscles and skin).
This new model of tracheal transplantation permits airflow
through the tracheal lumen as well as the elimination of inspis-
sated mucous and is therefore more likely to be physiologic than
the standard model (38, 39) in which a tracheal segment is trans-
planted into subcutaneous tissue in the recipient’s back.
All recipient animals received postoperative intramuscular im-
munosuppression (25 mg/kg/day cyclosporine; Bedford Labora-
tories) for 2 wk to model acute on chronic airway rejection, and
3 d of antibiotics (20 mg/kg/day cefazolin sodium; Apothecon)
to suppress procedure-related infections. All recipient animals
survived and were killed at a predefined interval of 3 wk after
transplantation. This interval was chosen based on preliminary 
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experiments suggesting that the most prominent cell infiltrates
were likely to occur 3 wk after transplantation. Grafts were har-
vested and embedded together with the native tracheas in Tissue
Freezing Medium™ (Triangle Biomedical Sciences) in a cryo-
mold or snap frozen in liquid nitrogen and stored at 
 
 
 
80
 
 
 
C until
the time of histological or mRNA evaluation.
 
Cell Isolation.
 
Infiltrating inflammatory cells were isolated
from transplanted airway graft tissue (40). In brief, tracheal grafts
were removed from recipients and rinsed with RPMI 1640 me-
dium (Life Technologies). Grafts were then minced using a scal-
pel in 3 ml RPMI 1640 medium containing 0.1% collagenase
type 4 (Worthington Biochemical), 0.1% soybean trypsin inhibi-
tor (Sigma-Aldrich), 50 U/ml DNase (Roche), 10% FBS, 10 
 
 
 
M
Hepes (Life Technologies), and 1% penicillin-streptomycin (Life
Technologies). The suspension was placed on an agitator at 37
 
 
 
C
for 30 min and the digestion mixture was passed through a 70-
 
 
 
m
nylon cell strainer (BD Biosciences) to remove undigested tissue and
debris. Mononuclear cells were purified from the cell suspensions
using density gradient centrifugation, using Lympholyte M (Accurate
Chemicals). Recipient spleen cells were also prepared by isolation
after centrifugation of cell suspensions and recovery of the pellet, fol-
lowed by red cell lysis using ammonium chloride buffer.
 
FACS
 
® 
 
Analysis.
 
Immunophenotyping of graft-infiltrating
leukocytes was accomplished by FACS
 
® 
 
analysis. Isolated mono-
nuclear cells were stained for multicolor FACS
 
® 
 
analysis using
PE-labeled anti–mouse CD3 and FITC-labeled anti–mouse
CD4, CD8 (BD Biosciences), and macrophage (F4/80; Caltag
Laboratories). Cells were prepared in staining buffer that con-
sisted of Ca
 
2
 
 
 
- and Mg
 
2
 
 
 
-free Dulbecco’s PBS (Mediatech) with
0.05% sodium azide and 1% FBS. After a 5-min incubation at
4
 
 
 
C with purified anti-2.4G2 (BD Biosciences) to reduce non-
specific binding of FcII/III receptors, the cells were incubated for
30 min at 4
 
 
 
C in the dark with the indicated fluorescent antibod-
ies (1:100). Next, cells were washed twice in staining buffer and
populations of lymphocytes and macrophages were then identi-
fied using a FACSCalibur
 
® 
 
system (BD Biosciences). Cell detec-
tor voltages were set using unstained lymphocytes isolated from
the spleen or cultured murine macrophages (RAW 264.7; Amer-
ican Type Culture Collection). To determine the absolute num-
bers of the specific lymphocyte populations, percentages of cells
established by FACS
 
® 
 
analysis were multiplied by the total num-
ber of lymphocytes isolated from grafts determined by manual cell
counts performed on a hemocytometer slide.
 
Histopathological Evaluation.
 
Frozen sections were cut 5-
 
 
 
m
thick and placed on glass slides (Fisher Scientific), after which sec-
tions were air dried, fixed for 15 min in acetone at 4
 
 
 
C, and
stored at 
 
 
 
20
 
 
 
C until needed. Histochemical staining was per-
formed for elastin (Accustain™; Sigma-Aldrich) to determine
graft luminal occlusion. Immunostaining was performed for von
Willebrand factor (vWf; rabbit anti–human vWf; Dako), smooth
muscle cells (mouse anti–actin 
 
 
 
-smooth muscle; Sigma-Aldrich),
CD3, CD4, and CD8 (hamster anti–mouse CD3, rat anti–mouse
CD4, and rat anti–mouse CD8; BD Biosciences), macrophage
(rat anti–mouse F4/80; Caltag Laboratories), neutrophil (rat anti–
mouse neutrophils; Cedarlane), iNOS and eNOS (polyclonal
rabbit anti–mouse iNOS and polyclonal rabbit anti–mouse
eNOS; Transduction Laboratories), and nitrotyrosine (polyclonal
rabbit anti–human nitrotyrosine; Upstate Biotechnology). To as-
certain cell proliferation in the transplanted grafts, in situ immu-
nohistochemical detection of bromodeoxyuridine (BrdU; BD
Biosciences) was performed. Recipient mice were injected intra-
peritoneally with 2.5 mg BrdU in PBS 24 and 2 h before sacri-
fice. After tissue harvest, slides were prepared from frozen sec-
 
tions in 0.01 M sodium citrate, pH 6.0, heated in a microwave to
90
 
 
 
C for 10 min, and cooled to room temperature followed by
regular staining technique. For all immunohistochemistry done
with a peroxidase readout, endogenous peroxidase was blocked
with 0.3% H
 
2
 
O
 
2
 
. For all stains, nonspecific blocking was accom-
plished with normal serum derived from the host species in
which the secondary antibody was prepared. Sections were then
incubated with a suitable concentration of the primary antibody
followed by the biotinylated secondary antibody. Immunodetec-
tion was performed using the Vectastain ABC Kit (Vector Labo-
ratories) and developed in Vector substrate kits followed by the
elastin stain, as well as a hematoxylin counterstain. As a negative
control, each section was incubated with normal serum instead of
the primary antisera.
Localization of intracellular chemokine expression (MIP-1
 
 
 
,
RANTES, and IL-1
 
 
 
) in WT allografts was determined by con-
focal microscopic examination (LSM410; Carl Zeiss MicroImag-
ing, Inc.) using multiparameter immunofluorescent staining tech-
niques. After blocking nonspecific binding and Fc receptors with
normal goat serum and the Fc receptor blocker anti-2.4G2 (BD
Biosciences), CD8
 
  
 
cells and macrophages were detected by
FITC-conjugated antibodies (rat anti–mouse CD8 and F4/80;
BD Biosciences and Caltag Laboratories, respectively). Sections
were then fixed and permeabilized using a Cytofix/CytopermTM
kit (BD Biosciences). Next, each section was incubated with rab-
bit anti–mouse antibody (MIP-1
 
 
 
, RANTES, and IL-1
 
 
 
; Cell
Sciences) or rabbit IgG as a negative control at 4
 
 
 
C for 30 min in
the dark. Intracellular chemokines were identified by incubating
the sections with fluorescein-conjugated secondary antibody (Al-
exa Fluor
 
® 
 
594 goat anti–rabbit IgG; Molecular Probes) followed
by a DAPI (4
 
 
 
,6-diamidino-2 phenylindole) counterstain.
To detect apoptosis in situ, the terminal deoxynucleotidyltrans-
ferase–mediated dUTP-digoxigenin nick-end labeling (TUNEL)
method was performed according to the manufacturer’s protocol
(in situ Cell Death Detection Kit; Roche). TUNEL
 
  
 
apoptotic
cells were compared with the results obtained by the immunohis-
tochemical detection of caspase-3 (polyclonal rabbit anti–human
caspase-3, which detects the p17 subunit of caspase-3 but not the
precursor form; R&D Systems) using adjacent serial sections for
colocalization. A double staining technique was then performed
to determine if the apoptotic cells were in fact T lymphocytes.
After labeling immunohistochemically for T lymphocytes using a
primary antibody to CD8 linked to alkaline phosphatase, apop-
totic cells were detected by the TUNEL method (visualized with
peroxidase substrate).
Morphometric measurements of cross-sectional areas and quan-
titative analysis for apoptotic cells in grafts was performed by
blindly tracing both epithelial and subepithelial areas using a com-
puter-assisted image analysis system (AxoCamHR; Carl Zeiss Mi-
croImaging, Inc.) and counting positively staining apoptotic cells
in five nonoverlapping high power (
 
 
 
400) fields from each of the
five sections of each group and expressing both data as a percent-
age of whole luminal area (inside the area of the cartilage ring) and
counting all cells identified by nuclear staining as the denominator.
 
Cytokine Assays.
 
To demonstrate the effect of recipient
iNOS and eNOS deficiency and pharmacologic iNOS inhibition
on serum levels of Th1 cytokines (TNF-
 
 
 
, IL-1
 
 
 
, IL-2, and total
IL-12; Amersham Biosciences), a Th2 cytokine (IL-4; Amersham
Biosciences) or two CC chemokines (MIP-1
 
 
 
 and RANTES;
R&D Systems), ELISAs were performed using commercial kits
according to the manufacturer’s instructions.
 
In Situ Hybridization.
 
To make RNA probes for in situ hy-
bridization, RT-PCR was performed using Superscript™ II (In- 
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vitrogen) with total RNA as template. Total RNA was prepared
from mouse tracheal tissue with TRIzol
 
® 
 
Reagent (Invitrogen).
Primers for mouse iNOS and eNOS were directed at 1055-
1078/1791-1768 (these sequence data are available from Gen-
Bank/EMBL/DDBJ under accession no. NM 010927) and 1265-
1287/2035-2015 (available from GenBank/EMBL/DDBJ under
accession no. NM 008713) of the cDNA, respectively, producing
737- and 771-bp products. The forward and reverse primers se-
quence for iNOS were 5
 
 
 
-CCCCGCTATGGCCGCTTT-
GATGTG-3
 
 
 
, 5
 
 
 
-AGGACTGTGGCTCTGACCCGTGAA 3
 
 
 
.
Those for eNOS were 5
 
 
 
-CACGCCGCCACAGCCTCCT-
TCAT-3
 
 
 
, 5
 
 
 
 CTCCCCGCCCAGCTCCTCCAG-3
 
 
 
. After re-
verse transcription, PCR was performed using the GeneAmp
PCR System 9600 (PerkinElmer) with 35 cycles at 94
 
 
 
C an-
nealling temperature. The PCR product mixture was run in a 1%
agarose gel and was recovered using a Qiagen
 
® 
 
II gel extraction
kit (QIAGEN). This was then inserted into pCR
 
®
 
II Vector using
the TA cloning method (Invitrogen). After the identity of the
RNA expression plasmid was confirmed by enzyme cut and se-
quencing (ABI Prism 310 Genetic Analyzer; PE Corp.), the plas-
mid was linearized with SpeI and NotI enzymes to allow in vitro
run-off synthesis of both sense- and antisense-oriented RNA
probes. Both sense and antisense probes were labeled with a
digoxigenin RNA labeling kit (Roche) and the labeled probes
were then purified. In situ hybridization was performed as pre-
viously described (41). In brief, slides were prefixed in 4%
paraformaldehyde and digested with 1 
 
 
 
g/ml proteinase K in Tris-
EDTA, pH 8.0, followed by fixation again using 4% paraformal-
dehyde. Sections were acetylated with 0.1 mol/L triethanolamine,
pH 8.0, with 0.25% (vol/vol) acetic anhydride, and then equili-
brated for 60 min in hybridization buffer consisting of 4
 
  
 
SSC,
50% formamide, 5% dextran sulfate, 0.1 mg/ml yeast tRNA, and
0.05 mg/ml salmon sperm DNA. Hybridization was performed
overnight at 45
 
 
 
C with either sense or antisense iNOS and eNOS
probes (1:25 dilution in prehybridization buffer). Sections were
subjected to stringent washes. After blocking with blocking buffer,
sections were incubated with a 1:100 dilution of sheep anti–digoxigenin
antibody (Digoxigenin detection kit; Roche) and color was allowed
to develop for 1 h. Sections were covered with aqueous mounting
medium until the time of inspection or photography.
 
Ribonuclease Protection Assay (RPA).
 
RPA was performed to
evaluate the expression of proinflammatory cytokines and poten-
tial apoptotic mediators in the graft 3 wk after transplantation.
Template RNA probes for RPA were designed based on the size
of its probe so that multiple target mRNAs to be analyzed could
be identified on a gel (Table I). The RNA probes were prepared
as described above. Total RNA was isolated from each tracheal
graft and 15 
 
 
 
g of each was used for the assay according to the
manufacturer’s protocol (RPA III™ kit; Ambion). In brief, in
vitro transcription (MAXIscript™ kit; Ambion) was performed
to generate antisense RNAs using T7 or SP6 RNA polymerase
with [
 
 
 
-
 
32
 
P]UTP (800 Ci/mmol; Amersham Biosciences). After
gel purifying, 
 
 
 
10 
 
  
 
10
 
4 
 
cpm each of full-length distinct probe
transcripts were hybridized in excess at 42
 
 
 
C overnight to the tar-
get RNAs. Free probes and nonhybridized single stranded RNA
were digested with RNase. Protected fragments were separated
on a 5% denaturing acrylamide gel and quantified by autoradiog-
raphy using BioMax™ film (Eastman Kodak Co.) at 
 
 
 
80
 
 
 
C. Ab-
sorption values were obtained by densitometry scanning (Na-
tional Institutes of Health (NIH) Image 1.62; NIH) of cDNAs.
Expression of each band was normalized with its corresponding 
 
 
 
actin band, and this ratio was then normalized with that of the
isograft sample for each experiment.
 
Statistics.
 
Data are expressed as mean 
 
  
 
SEM. All statistical
comparisons were performed using a commercially available sta-
tistical package for the Macintosh personal computer (Stat View-J
5.0™; SAS Institute). One-way ANOVA and the Scheffe post-
hoc test was used to compare conditions among the four groups.
Differences were considered significant at the level of P 
 
  0.05.
Results
Time Course of Graft Histopathology. Pilot studies per-
formed during the development of the airway transplant
model failed to show histological evidence of tissue necrosis
in microscopic sections evaluated at various time points. To
determine angiogenesis in these airway allografts (trans-
planted without a vascular pedicle), capillarization was de-
tected by immunostaining of endothelial cells with an anti-
body that recognizes vWf (Fig. 1 B). These data show
many small vessels in the grafts, including in newly formed
obstructing lesions. Histopathological evaluation of B10.A
airway allografts harvested 4–6 h and 3, 6, and 10 wk after
transplantation into C57BL/6J WT recipients (n   4 each)
demonstrated the sequential progression of airway allograft
rejection. Mononuclear cell infiltration into the allografts
was primarily observed in the subepithelial layer (SEL) as
early as 2 wk (unpublished data), but the intensity of the
infiltrate increased at both the epithelial layer (EL) and SEL
during the period from 3–4 wk after transplantation. At
these time points, both layers were thickened, leading to a
partial concentric graft luminal occlusion (Fig. 1 C shows
representative sections and pooled data are quantified in
D). Most infiltrating cells in the SEL and EL regions of the
allografts receded after 3–4 wk and at 6 wk, epithelial disso-
ciation from the basement membrane was noted. After epi-
thelial denudation, little if any inflammatory infiltrate was
observed. By 10 wk after transplantation, epithelium ap-
peared flattened, ciliary structures were no longer visible,
Table I. PCR Primer Sequences Were Synthesized to Detect the 
Indicated Mouse Cytokines and Apoptotic Mediators
Template Sequence Location GenBank
Probe 
length (bp)
MIP-1  696-717 / 1047-1021 X53372 352
RANTES 128-151 / 450-431 M77747 323
IFN-  539-558 / 835-816 K00083 297
TNF-  1655-1678 / 1916-1893 M38296 262
  actin provided by Ambion — 245
iNOS 1243-1270 / 1453-1426 NM010927 211
eNOS 1319-1345 / 1504-1476 NM008713 186
nNOS 3096-3119 / 3261-3240 NM008712 166
p53 1269-1292 / 1423-1400 X01237 155
IL-1  788-811 / 921-899 M15131 134
Sequences used to make template RNA probes for RNase protection
assays, probe lengths, GenBank accession numbers, and expected size
of protected RNA fragments are indicated.1325 Minamoto and Pinsky
and the subepithelial space was thickened with substantial
collagen accumulation. As in human OB (5), immunohis-
tochemical examination revealed little if any smooth mus-
cle cells in the obstructive airway lesion, although as ex-
pected, the normal airway musculature stains quite clearly
(unpublished data). The membranous and airway muscula-
ture areas of the cartilaginous “C” rings appeared relatively
unaffected throughout the observation period. The result
of assays for cell proliferation by in situ immunohistochem-
ical detection of BrdU demonstrated positive staining in
some (but not many) nuclei in the obstructive airway lesion
(unpublished data). These results indicate that proliferative
change is not a major culprit in the developing obstructive
airway lesion. Based on these observations, to establish the
role of NOS, grafts in subsequent experiments were har-
vested 3 wk after tracheal transplantation.
Quantification of Graft Mononuclear Cell Infiltration. The
prominent mononuclear cell infiltrate in airway allografts
was comprised primarily of T cells, as determined by im-
munohistochemical analysis for the pan-T cell–marked
CD3 (Fig. 2, a–e). These airway inflammatory lesions with
lymphocytic predominance are indistinguishable histologi-
cally from lymphocytic bronchitis observed in humans (5).
Identification of subpopulations of graft-infiltrating CD4 
(Fig. 2, f–j) and CD8  (Fig. 2, k–o) T cells, as well as F4/
80  macrophages (Fig. 2, p–t), was also performed. Abso-
lute and relative numbers of allograft-infiltrating leuko-
cytes, including CD3  CD4  T cells, CD3  CD8  T cells
(Fig. 2 u), and F4/80  macrophages (Fig. 2 v) were deter-
mined by FACS® analysis and manual cell counting. Con-
cordant with the immunohistochemical data, analysis of
cells extracted from graft tissue indicates that infiltrating
lymphocytes in allografts from WT recipients (n   7) are
predominantly CD3  CD8  T cells (223   103   9.9  
103/graft for CD3  CD8 , 151   103   6.7   103/graft
for CD3  CD4 ). In contrast, lymphocytic infiltration was
markedly reduced with either recipient iNOS deletion (n   5;
26-fold reduction for CD3  CD8  and 18-fold reduction
for CD3  CD4 ) or pharmacologic inhibition of iNOS
with L-NIL (n   6; sevenfold reduction for CD3  CD8 
and threefold reduction for CD3  CD4 ). Interestingly,
pharmacological iNOS blockade showed a more potent
Figure 1. (A) New model of mu-
rine tracheal transplantation. The
graft can fulfill its function as an air-
way by placing the proximal and dis-
tal graft anastomoses in the native
trachea. This environment allows ep-
ithelium in the graft to be exposed to
air and drain mucous through the
anastomosis. Arrow, tracheal graft;
arrowhead, native trachea. (B) Im-
munostaining for vWf in an allograft
from a WT recipient. Arrows, anti–
vWf-reactive capillaries. (C) Repre-
sentative Verhoeff’s-Van Gieson staining of transverse sections (low power magnification for a–d, high power magni-
fication for e–h) through WT allografts (right side) with native trachea (left side) revealing the time course of
the rejection process. After tracheal transplant (0 wk; a and e), mononuclear cells accumulated in the EL as well as
SEL at 3 wk (b and f), with subsequent diminution by 6 wk (c and g). After 6 wk, epithelial cells were observed to
dissociate from the basement membrane (BM). By 10 wk (d and h), epithelium appeared flattened with loss of ciliary
structures and the subepithelial space was thickened with substantial collagen deposition. The time course of luminal
occlusive lesions in the EL and SEL shown in D demonstrates that the intensity of the infiltrate corresponds with sub-
sequent graft luminal (GL) occlusion. Comparing luminal patency with isografts, which exhibited near-complete pa-
tency, allografts were maximally occluded 3 wk after transplantation. n   4 for each group; *, P   0.05; bar, 50  m.1326 iNOS and eNOS in Obliterative Bronchiolitis
suppression of CD3  CD8  T cells infiltration than that of
CD3  CD4  T cells. iNOS /  recipients exhibited similar
degrees of suppression of both T cell subtypes. eNOS / 
recipients (n   5), however, did not show any significant
difference in graft CD4  T cell, CD8  T cell, or macro-
phage infiltration compared WT recipients. There was also
a decrease in the number of macrophages from allografts
from iNOS /  recipients (eightfold reduction) and L-NIL–
treated WT recipients (twofold reduction) compared with
both allografts from WT and eNOS /  recipients. These
quantitative data suggest that iNOS expression, but not
eNOS expression, increases absolute numbers of infiltrating
T cell subpopulations and macrophages. Immunohis-
tochemical staining revealed a relative paucity of neutro-
phils in all groups (unpublished data). Isografts demon-
strated no obvious cellular infiltrates on histological
examination, and correspondingly, no detectable infiltrates
upon lymphocyte isolation.
Morphometric analysis of WT allografts revealed a con-
cordance between the thickening of each of the airway lay-
ers leading to luminal occlusion and lymphocytic infiltrates
(Fig. 3 a). Compared with these results in WT recipients, al-
lografts transplanted into iNOS /  recipients showed signif-
icantly less luminal narrowing with a concordant reduction
in the numbers of infiltrating CD3  CD4  and CD3  CD8 
T cells. On the other hand, eNOS /  recipients showed
neither any significant difference in luminal obstruction or
influx of T lymphocytes compared with WT allograft recip-
ients. Pharmacologic inhibition of recipient iNOS with
L-NIL (5 mg/kg/day) 3 wk after transplantation to both
WT (n   10) and eNOS /  (n   5) recipients revealed sig-
nificant reduction in the luminal obstruction of allografts
compared with WT and eNOS /  allograft recipients.
In contrast to the original scenario, in which iNOS / 
allografts transplanted into iNOS /  recipients exhibited
significantly reduced luminal occlusion (29   2% vs. 53  
2% for iNOS /  allografts transplanted into iNOS /  recip-
ients), graft luminal occlusion in iNOS /  allografts trans-
planted into iNOS /  recipients (n   5) 3 wk after trans-
plantation was 49   2%. These differences could not be
accounted for by differences in background strain, because
for iNOS /  trachea transplanted into iNOS /  recipients,
luminal occlusion was similar when the reverse background
strain combination (i.e., C57Bl/6J donors transplanted into
B10.A recipients) was used (n   5, luminal occlusion 49  
1%; Fig. 3 b). These data suggest that iNOS expressed by
graft-infiltrating leukocytes, rather than by airway epithe-
lium, exerts the dominant influence on airway rejection.
Quantification of Lymphocyte Apoptosis. Apoptosis of T
cells represents a major mechanism of immune modulation.
Therefore, evidence for apoptosis of graft-infiltrating T
cells was ascertained using the TUNEL method (Fig. 4,
Figure 2. Immunohistochemical staining of the pan-T
cell marker CD3 (a–e; brown), as well as CD4  (f–j;
brown), CD8  (k–o; red) T cells, and F4/80  (p–t;
brown) macrophages in sections from grafts transplanted
into isogeneic (a, f, k, and p), allogeneic WT (b, g, l, and
q), iNOS /  (c, h, m, and r), eNOS /  (d, i, n, and s)
recipients, and L-NIL–treated WT (e, j, o, and t) recipi-
ents 3 wk after transplantation. Quantitative analysis of
mononuclear cell infiltrates by FACS®, shown as abso-
lute numbers of recovered CD3   CD4   and CD3 
CD8  T cells (u), and F4/80  macrophages (v) in each graft from each group. Bar, 50  m; *, P   0.05 versus allografts from WT recipients; #, P   0.05
versus allografts from iNOS /  recipients; †, P   0.05 versus allografts from eNOS /  recipients.1327 Minamoto and Pinsky
a–d), and further corroborated immunohistochemically by
colocalizing caspase-3 expression in the same cells in adja-
cent sections (Fig. 4, e–h). Caspases play an important role
in the execution phase of apoptosis. Caspase-3 is one of the
downstream effector caspases (42), activated by proapop-
totic signals triggered by cytokines (43, 44) or through cell
death receptors (45), which cleaves cytoskeletal and nuclear
proteins to induce apoptosis. Both apoptotic cells and
caspase-3 activation colocalize predominantly to the EL,
moreso than the SEL. Most apoptotic cells were identified
as CD8  T lymphocytes with a double staining technique
(Fig. 4, i–l). The frequency of apoptotic T lymphocyte
TUNEL positivity in WT recipients of allografts was sig-
nificantly higher in the EL than that seen in WT recipients
Figure 3. (a) Analysis of tracheal graft sections 3 wk after transplanta-
tion. Representative sections (left) and morphometric analysis of sections
(right) for each of the indicated conditions. Isografts were WT and al-
lograft recipients were either WT, iNOS / , or eNOS / . The effect of
pharmacologic recipient iNOS inhibition with L-NIL (5 mg/kg/day for
3 wk after transplantation) in WT and eNOS /  recipients was also ex-
amined. Allografts placed in iNOS /  or iNOS-inhibited recipients dem-
onstrated significantly reduced luminal obliteration compared with WT
and eNOS /  allograft recipients. In contrast, recipient eNOS deficiency
was associated with similar degrees of luminal occlusion as WT allograft
recipients. *, P   0.05 versus allografts from WT recipients; #, P   0.05
versus allografts from iNOS /  recipients; †, P   0.05 versus allografts
from eNOS /  recipients. (b) The effect of epithelial versus leukocyte-
derived iNOS on graft luminal occlusion. Donor tissue and recipient
genotypes were either iNOS /  or iNOS / , as indicated. Effect of back-
ground strain is also indicated here. Genotypes that are underlined rep-
resent B10.A strain background. Genotypes that are not underlined repre-
sent C57BL/6J. Note that the leftmost three bars represent the same data
as is shown in a, repeated here to facilitate comparison. *, P   0.05.
Figure 4. Apoptotic cells were detected using the in situ TUNEL la-
beling method (a–d; arrows) and further corroborated immunohis-
tochemically by colocalizing caspase-3 expression in the same cells in ad-
jacent sections (e–h; arrows). Double staining for apoptotic CD8  T
lymphocytes (i–l; arrows) is detected by black nuclear labeling for apopto-
sis and red cytoplasmic staining for CD8. Apoptosis of CD8  T lympho-
cytes (arrows) was most abundant in the EL of allografts placed in WT
and eNOS /  recipients. The graph (m) shows quantitative T lympho-
cyte apoptotic activity in both the EL and SEL of the graft. Apoptosis of
T lymphocytes was reduced by recipient iNOS deficiency. *, P   0.05
versus allografts from WT recipients; #, P   0.05 versus allografts from
iNOS /  recipients; bar, 50  m.1328 iNOS and eNOS in Obliterative Bronchiolitis
of isografts (Fig. 4 m). Compared with WT allograft recipi-
ents, apoptotic cells were much less frequently observed in
the EL of allografts placed in iNOS /  recipients. eNOS / 
allograft recipients showed a very slight increase in apop-
totic cells in the EL. These results indicate that apoptosis of
graft-infiltrating T cells is increased in the EL of allografts,
is markedly reduced by recipient iNOS deficiency, and
slightly increased by recipient eNOS deficiency. Oblitera-
tion of the airway lumen appears to parallel quite closely
the degree of lymphocytic infiltration as well as the apop-
totic T cell activity detected in the lesions.
Colocalization of iNOS mRNA/Protein and Nitrotyrosine
Immunoreactivity. In situ detection of iNOS mRNA as
well as immunohistochemical detection of iNOS protein
were performed to determine whether graft iNOS expres-
sion is predominantly a function of in situ induction within
the allograft proper, or whether migrating leukocytes rep-
resent the predominant source. Although iNOS mRNA
and protein were faintly detectable in isografts (Fig. 5, a and
e), they were prominently localized in the EL of allografts
from both WT (Fig. 5, b and f) and eNOS /  (Fig. 5, d
and h) recipients. iNOS was strongly expressed in both the
epithelial cells and infiltrating leukocytes, whereas eNOS
immunoreactivity was limited to the surface epithelial cells
of both isografts and allografts (unpublished data). There
were no hybridization signals detected in adjacent serial
sections hybridized with both sense iNOS and eNOS
RNA probes (unpublished data). In iNOS /  recipients,
iNOS immunopositivity was limited to the surface epithe-
lium of the iNOS /  allografts (Fig. 5 g). Interestingly,
iNOS mRNA and protein expression were enhanced in
grafts from eNOS /  recipients, whereas there was no up-
regulation of both eNOS mRNA and protein expression in
grafts from iNOS /  recipients (unpublished data). These
data indicate that there is compensatory up-regulation of
iNOS in allografts placed in eNOS null recipients.
In a milieu in which oxygen radicals and NO are pro-
duced in abundance in very close proximity, such as in al-
lograft rejection, peroxynitrite forms rapidly as the adduct
of superoxide and NO. Peroxynitrite is a highly reactive
compound that promotes the nitration of tyrosine residues
in tissue proteins, which can then be detected immunohis-
tochemically using an antibody that specifically recognizes
nitrotyrosine (46). Immunohistochemical studies demon-
strated abundant expression of nitrotyrosine in tracheal al-
lografts, specifically in epithelial cells and graft-infiltrating
lymphocytes from WT and eNOS /  recipients, but not
for iNOS /  recipients (unpublished data). These data in-
dicate that iNOS, rather than eNOS, is chiefly responsible
for the production of NO that leads to the formation of
peroxynitrite in tracheal allografts. Taken together with the
data showing iNOS gene null or iNOS-inhibited allografts
to be protected from luminal obliteration (Fig. 3 a), these
data raise the specter of a causal link between peroxynitrite
formation and the endoluminal obliterative process (47).
mRNA Expression of Chemokines, Proapoptotic Mediators,
and NOS Isoforms. To determine whether chemoattrac-
tant and apoptotic mediators were up-regulated in concor-
dance with the influx and deletion of graft infiltrating
lymphocytes, multiprobe RPAs were performed on tissue
samples obtained 3 wk after transplantation (Fig. 6 a).
Compared with isografts, normalized messages of the CC
chemokines, MIP-1  (Fig. 6 b) and RANTES (Fig. 6 c),
were significantly (P   0.05) up-regulated in the allo-
grafts from WT recipients (33-fold increase for MIP-1 
and 14-fold increase for RANTES) and eNOS /  recipi-
ents (32-fold and 11-fold increase, respectively). Allografts
from iNOS /  recipients, however, showed significantly
less expression of CC chemokines compared with the
WT allografts. These findings suggest that iNOS, but not
eNOS, plays a significant role in the CC chemokine up-
regulation, which results in recruitment of CD8  T cells.
On these blots, IFN-   mRNA was not detected and
TNF-  was only faintly expressed (Fig. 6 d). Expression of
mRNAs for the tumor suppressor p53 (Fig. 6 e) and IL-1 
(Fig. 6 f) paralleled the results seen in histologic sections
stained for apoptotic immunoreactivity. Compared with
isografts, normalized message for p53 and IL-1  were up-
regulated in the allografts from WT recipients (ninefold and
fivefold increase, respectively; P   0.05 each) and eNOS / 
Figure 5. Analysis of iNOS mRNA expression by in situ hybridization
and iNOS immunoreactivity in airway grafts. Both iNOS mRNA and
protein production are modestly detected in the EL of isografts (a and e),
but strongly detected in epithelial cells and inflammatory cells from al-
lografts placed in WT recipients (b and f). Allografts from iNOS /  recip-
ients exhibited virtually no iNOS mRNA (c) or protein expression, ex-
cept faint detection observed on the surface of the EL (g). However,
elevated iNOS mRNA (d) and strong iNOS immunoreactivity (h) was
identified in allografts from eNOS /  recipients. Bar, 50  m.1329 Minamoto and Pinsky
recipients (11-fold and ninefold increase, respectively; P  
0.05 each). In contrast, allografts from iNOS /  recipients
showed significantly less expression of both mRNA species
compared with WT allografts. These data, too, corre-
sponded with the increased apoptotic immunoreactivity
observed on histological sections of WT and eNOS /  al-
lografts. mRNA levels of p53 and IL-1  were diminished
(to isograft levels) in allografts transplanted into iNOS null
recipients, in concordance with the apoptosis data shown in
Fig. 4.
Because the lack of one NOS isoform could theoreti-
cally, especially under stress conditions, lead to a compen-
satory induction of an alternate NOS isoform, mRNA lev-
els for the three NOS isoforms were quantified by RNase
protection assay in this tracheal transplant model. mRNA
levels of iNOS were significantly increased in the allografts
from WT and eNOS /  recipients compared with isografts
(15-fold and 12-fold increase, respectively; P   0.05 each),
whereas no significant increase was shown in the iNOS / 
recipients (Fig. 6 g; note that some baseline level of NOS
may have been detected secondary to NOS expression in
the allograft material rather than in infiltrating cells). eNOS
mRNA expression in grafts was detected at the same low
levels in all groups (Fig. 6 h). Expression of nNOS mRNA
was increased in the allografts from WT and eNOS / 
recipients (sixfold increase for both; P   0.05) compared
with isografts (Fig. 6 i).
Cytokine Expression and Localization. Recipient cytokine
levels in serum samples (n   10) from each group were
measured 3 wk after transplantation (Fig. 7, a–g). In con-
trast to the levels of cytokines that were observed in isoge-
neic recipients, the levels of chemokines, MIP-1   and
RANTES, and IL-1  in WT and eNOS /  allograft recip-
ients were up-regulated after airway allograft transplanta-
tion. Recipient iNOS gene deficiency and pharmacologic
inhibition, however, significantly suppressed MIP-1  pro-
duction with trends toward reduced levels of other inflam-
matory chemokines/cytokines. Although some levels of
some Th1 cytokines were not affected by either airway
transplantation nor iNOS status (TNF- , IL-12), there
were strong trends shown toward up-regulation of IL-2.
Unexpectedly, WT airway allograft transplantation caused
an increase in serum levels of IL-4 (a Th2 cytokine) with
decreased levels in iNOS gene null mice.
Colocalization of intracellular chemokine (MIP-1  and
RANTES) and proinflammatory cytokine (IL-1 ) expres-
sion was determined by confocal microscopic examination
of WT allograft tissue. Allograft-infiltrating cells that ex-
pressed MIP-1  were identified primarily as F4/80  mac-
rophages (Fig. 7 i) much more so than CD8  T cells (Fig. 7
h). CD8  T cells, however, expressed RANTES protein,
evidenced by the colocalization of the fluorescent signals
(Fig. 7 j). Although IL-1  expression was mainly localized
in the epithelial lining (Fig. 7 k), it was also detected in F4/
80  macrophages (Fig. 7 l). CD8  T cells do not appear to
be sites of IL-1  synthesis (Fig. 7 k).
Discussion
To date, the underlying causes of OB remain elusive as they
are likely multifactorial. Nevertheless, given the importance of
OB as the prime limitation to long-term success with lung
transplantation, understanding potential contributory mecha-
nisms remains an important goal. Histologically, it appears that
OB develops as a part of the immune response, as the result of
repeated bouts of allograft airway inflammation that matures
by tissue scarring, with resultant luminal obliteration. Because
the bronchial/bronchiolar epithelium is one of the prime tar-
gets of lung rejection (48, 49), alloantigen-dependent airway
epithelial damage occurring shortly after transplantation, dur-
ing the lymphocytic bronchitis phase, can foreshadow the
eventual loss of airway function.
Figure 6. Simultaneous quantitation of multiple mRNA species encod-
ing chemokines, proapoptotic mediators, and NOS isoforms in grafts from
each group were examined using multiprobe RNase protection assays 3
wk after transplantation (n   5 for each). 15  g of total RNA was hybrid-
ized to each of the 10 antisense riboprobes (refer to Table I) (a) The inten-
sity of each protected band was determined by densitometry, with values
normalized first to the corresponding   actin band and then relative to the
normalized value for each isograft experiment (b–i). *, P   0.05 versus al-
lografts from WT recipients; #, P   0.05 versus allografts from iNOS / 
recipients; †, P   0.05 versus allografts from eNOS /  recipients.1330 iNOS and eNOS in Obliterative Bronchiolitis
NO is a well-recognized immunomodulatory gas that
has special importance in the pathobiology of lung trans-
plant rejection. It is exhaled in great quantities during lung
transplant rejection, particularly during the lymphocytic
bronchitis and early OB stages (50), and expression of the
inducible enzyme responsible for its synthesis increases
greatly during the active premonitory phases of OB, partic-
ularly in the bronchial epithelium (10). In contrast to the
recognized up-regulation of iNOS during chronic lung
transplant rejection, eNOS is down-regulated (9, 10).
These studies suggest that in striking contrast to cardiac
allograft vasculopathy, where lack of the iNOS gene exac-
erbated cardiac transplant arteriosclerosis (30), in the air-
ways, lack of iNOS is beneficial. iNOS can play a role as a
potential mediator of cardiac chronic rejection by modu-
lating mononuclear cell expansion and neointimal vascular
smooth muscle migration or proliferation (28, 30). Endo-
thelially derived NO appears to inhibit atherogenesis by
suppressing expression of endothelial adhesion receptors
(51), smooth muscle cell–derived chemokines (52), and
activated leukocyte-derived superoxide radicals (53).
Therefore, in a cardiac allograft model, it is not particu-
larly surprising that iNOS suppresses vasculopathy. The
data presented here, however, in transplanted airways, is
diametrically opposite. The presence of the iNOS gene
exacerbates LB and the luminal airway narrowing that is
similar to OB. Our data show that recipient mice lacking
the iNOS gene, or those treated with a specific iNOS in-
hibitor, exhibit significant protection against (a) lympho-
cytic bronchitis, (b) local induction of proinflammatory
and proapoptotic mediators, (c) apoptosis of graft-infiltrat-
ing cells, and (d) late development of OB. In addition,
leukocyte-derived iNOS rather than epithelium-derived
iNOS appears to be most responsible for the development
of the pathological airway lesion. These data indicate that
chronic airway rejection and chronic vascular rejection
Figure 7. Serum cytokine levels measured by ELISA 3 wk after trans-
plantation (n   10 for each group; a–g.) Colocalization of intracellular
chemokine expression (MIP-1 , RANTES, and IL-1 ) and leukocyte
immunophenotype was determined by confocal microscopic examination
using immunofluorescent staining technique (h–l). Intracellular chemo-
kines were identified by red emission after the application of an excitation
wavelength of 594 nm. CD8  T cells (h, j, and k) and F4/80  macro-
phages (i and l) were labeled with FITC, which was detected as a green
emission after the application of an excitation wavelength of 488 nm. Sites
of colocalization (yellow) are indicated by arrows and epithelial cells that
express IL-1  are indicated by the arrowhead. *, P   0.05 versus allografts
from WT recipients; #, P   0.05 versus allografts from iNOS /  recipi-
ents; †, P   0.05 versus allografts from eNOS /  recipients; bar, 5  m.1331 Minamoto and Pinsky
differ fundamentally from each other, particularly with re-
spect to the ultimate causes of luminal obstruction. There
are several possible explanations for these differences. Kog-
lin et al. (30) posit that iNOS prevents neointimal smooth
muscle migration and hence, exerts a suppressive effect on
vascular thickening. In contrast, our studies indicate that
smooth muscle cells do not represent a significant compo-
nent of the obstructive airway lesion. Rather, early on,
there is a lymphocytic predominance and later, acellular
collagenous material accumulates with ongoing epithelial
damage. This is pathologically quite similar to the OB that
develops in humans (5), in which fibrous scarring repre-
sents the dominant feature.
Chemotaxis for both CD4  and CD8  T cells is an im-
portant mechanism in allograft rejection. Local production
of proiflammatory chemokine or cytokine derived from
mononuclear cells have been suggested to trigger the rejec-
tion process observed in lung transplant recipients (54–57).
Both Th1 and Th2 cytokines contribute to the develop-
ment of allograft rejection and their transcript levels have
been correlated with graft rejection severity (58), which is
why helper T lymphocytes represent major targets of im-
munosuppressive therapy. In this study, we demonstrate
that iNOS increases mRNA and protein for some, but not
all, Th1 cytokines and also does so for a Th2 cytokine (IL-
4). eNOS has essentially no effect on any measured cyto-
kine in this model. Because of the striking recruitment of
CD3  CD8  T cells to allografts, which was increased sig-
nificantly by iNOS in parallel with increased induction of
CC chemokines, it is reasonable to posit a causal relation-
ship between iNOS expression, chemokine induction, and
recruitment of alloeffector cytotoxic T lymphocytes.
Confocal microscopic studies showed that once re-
cruited, graft-infiltrating lymphocytes and monocytes are
likely to participate in the propagation and amplification of
the alloimmune response to the transplanted airway. Cyto-
toxic T lymphocytes are known to participate in establish-
ing the local cytokine environment by producing CC che-
mokines (59, 60), a result that is supported by the confocal
microscopic studies that identify both CD8  T cells and
macrophages as sites of cytokine/chemokine production.
Either recipient iNOS deficiency or pharmacologic inhibi-
tion of iNOS mitigated lymphocytic and macrophage infil-
tration significantly, and interestingly, changed the pre-
dominant T cell population from CD3  CD8  to CD3 
CD4  T cells infiltrate, with a marked reduction in all T
cells. These data indicate that iNOS, but not eNOS, plays a
critical regulatory role in the recruitment of T lympho-
cytes, particularly CD3  CD8  T cells, during the process
of airway rejection.
Some comment is necessary regarding the new model of
airway transplantation presented in this study. Previous
murine airway transplant models in mice (39) involved het-
erotopic airway implantation into subcutaneous tissue.
However, the conditions of these grafts is airless, and in our
own experience (unpublished data), we found that these
heterotopic grafts became clogged intraluminally with se-
cretions, which is less physiologic than the intraluminal air
flow permitted by our model. This air flow–permissive
model is likely to be more relevant in studies in which the
role of a biologic gas, such as NO, is being examined. Bio-
logically meaningful model-related differences may account
for the divergence of our results with those reported in a
rat tracheal transplant model. In studies in which rat tra-
cheal segments were transplanted intraperitoneally (31), a
relatively, but not completely, selective iNOS inhibitor
(aminoguanidine) did not alter CD4  nor CD8  T cell in-
filtration, and although early luminal obliteration was ac-
celerated, at 30 d, no differences in airway obliteration
were seen between treated and untreated groups.
In summary, our results indicate that during the process
of airway rejection, up-regulation of iNOS occurs in the
allograft epithelium as well as in graft-infiltrating leuko-
cytes. In this critical region, iNOS, especially that derived
from leukocytes, promotes massive lymphocyte influx and
their subsequent apoptosis, coinciding with the release of
chemotactic as well as proapoptotic mediators, leaving a
smoldering lesion in which fibrosis and eventual luminal
obliteration take place. These data suggest that OB is fun-
damentally different than cardiac allograft vasculopathy,
where iNOS induction appears to be protective, and sug-
gest that iNOS inhibitors may actually have some role to
play in OB prevention.
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